# Orelabrutinib in Combination With Thiotepa in Refractory and Relapsed Primary CNS Lymphoma

> **NCT05021770** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Huiqiang Huang** · enrollment: 29 (estimated)

## Conditions studied

- Refractory and Relapsed Primary CNS Lymphoma
- PCNSL
- Non Hodgkin Lymphoma

## Interventions

- **DRUG:** Orelabrutinib
- **DRUG:** Orelabrutinib
- **DRUG:** Thiotepa

## Key facts

- **NCT ID:** NCT05021770
- **Lead sponsor:** Huiqiang Huang
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-12
- **Primary completion:** 2022-12
- **Final completion:** 2024-06
- **Target enrollment:** 29 (ESTIMATED)
- **Last updated:** 2021-08-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05021770

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05021770, "Orelabrutinib in Combination With Thiotepa in Refractory and Relapsed Primary CNS Lymphoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05021770. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*